These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18845089)

  • 1. Efficacy of a day-care program in the treatment of psoriasis.
    Zhang J; Adam DN; Stebbing E; Gerbrandt J; Lui H; Shapiro J; Zhou Y
    J Cutan Med Surg; 2008; 12(5):211-6. PubMed ID: 18845089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
    Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
    Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
    Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principal determinants of the length of remission of psoriasis vulgaris after topical, NB-UVB, and PUVA therapy: a follow-up study.
    Coimbra S; Oliveira H; Belo L; Figueiredo A; Rocha-Pereira P; Santos-Silva A
    Am J Clin Dermatol; 2013 Feb; 14(1):49-53. PubMed ID: 23329079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis.
    Moul DK; Routhouska SB; Korman NJ
    J Cutan Med Surg; 2007; 11(4):132-6. PubMed ID: 17601420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris.
    Torras H; Aliaga A; López-Estebaranz JL; Hernández I; Gardeazabal J; Quintanilla E; Mascaró JM
    J Dermatolog Treat; 2004 Apr; 15(2):98-103. PubMed ID: 15204160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks.
    Sivanesan SP; Gattu S; Hong J; Chavez-Frazier A; Bandow GD; Malick F; Kricorian G; Koo J
    J Am Acad Dermatol; 2009 Nov; 61(5):793-8. PubMed ID: 19766350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study.
    Coimbra S; Oliveira H; Reis F; Belo L; Rocha S; Quintanilha A; Figueiredo A; Teixeira F; Castro E; Rocha-Pereira P; Santos-Silva A
    Am J Clin Dermatol; 2010 Dec; 11(6):423-32. PubMed ID: 20429617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis.
    Khandpur S; Sharma VK
    Clin Exp Dermatol; 2011 Aug; 36(6):613-6. PubMed ID: 21507036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive evaluation of tacalcitol plus puva versus tacalcitol plus UVB-NB in the treatment of psoriasis: "right-left intra-individual pre/post comparison design".
    Brazzelli V; Barbagallo T; Prestinari F; Rona C; De Silvestri A; Trevisan V; Borroni G
    Int J Immunopathol Pharmacol; 2005; 18(4):755-60. PubMed ID: 16388725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE;
    Lancet; 2005 Oct 15-21; 366(9494):1367-74. PubMed ID: 16226614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.
    Bagel J
    J Drugs Dermatol; 2011 Apr; 10(4):366-71. PubMed ID: 21455546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
    Bissonnette R; Iversen L; Sofen H; Griffiths CE; Foley P; Romiti R; Bachinsky M; Rottinghaus ST; Tan H; Proulx J; Valdez H; Gupta P; Mallbris L; Wolk R
    Br J Dermatol; 2015; 172(5):1395-406. PubMed ID: 25418186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A global approach to psoriatic patients through PASI score and Skindex-29.
    Prignano F; Ruffo G; Ricceri F; Pescitelli L; Lotti T
    G Ital Dermatol Venereol; 2011 Feb; 146(1):47-52. PubMed ID: 21317856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.